Growth and Growth Hormone Use in Osteogenesis Imperfecta - Osteogenesis Imperfecta - page 250

hormone (GH) administration: differential effects on bone den-
sity and body composition in men with adult-onset GH dei-
ciency. J Clin Endocrinol Metab 2000;85(3):970-6.
[28] Martin DD, Heckmann C, Ranke MB, Binder G, Thodberg HH.
Differentiation of GH effects on metacarpal bone in children
with GHD. Bone 2009;45:S60.
[29] Murray RD, Adams JE, Shalet SM. A densitometric and mor-
phometric analysis of the skeleton in adults with varying
degrees of growth hormone deiciency. J Clin Endocrinol
Metab 2006;91(2):432-8.
[30] Schweizer R, Martin DD, Schwarze CP, Binder G, Georgiadou
A, Ihle J, et al. Cortical bone density is normal in prepubertal
children with growth hormone (GH) deiciency, but initially
decreases during GH replacement due to early bone remodel-
ing. J Clin Endocrinol Metab 2003;88(11):5266-72.
[31] Giustina A, Veldhuis JD. Pathophysiology of the neuroregula-
tion of growth hormone secretion in experimental animals and
the human. Endocr Rev 1998;19(6):717-97.
[32] Leung DW, Spencer SA, Cachianes G, Hammonds RG, Collins
C, Henzel WJ, et al. Growth hormone receptor and serum
binding protein: puriication, cloning and expression. Nature
1987;330(6148):537-43.
[33] Jones JI, Clemmons DR. Insulin-like growth factors and their
binding proteins: biological actions. Endocr Rev 1995;16(1):3-34.
[34] Holly J, Perks C. The role of insulin-like growth factor binding
proteins. Neuroendocrinology 2006;83(3-4):154-60.
[35] Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H,
Kangawa K. Ghrelin is a growth-hormone-releasing acylated
peptide from stomach. Nature 1999;402(6762):656-60.
[36] Takaya K, Ariyasu H, Kanamoto N, Iwakura H, Yoshimoto A,
Harada M, et al. Ghrelin strongly stimulates growth hormone
release in humans. J Clin Endocrinol Metab 2000;85(12):4908-11.
[37] Giustina A, Wehrenberg WB. Inluence of thyroid hormones on
the regulation of growth hormone secretion. Eur J Endocrinol
1995;133(6):646-53.
[38] Giustina A, Wehrenberg WB. The role of glucocorticoids in the
regulation of growth hormone secretion: mechanisms and clin-
ical signiicance. Trends Endocrinol Metab 1992;3(8):306-11.
[39] Martha Jr. PM, Rogol AD, Veldhuis JD, Kerrigan JR, Goodman
DW, Blizzard RM. Alterations in the pulsatile properties of cir-
culating growth hormone concentrations during puberty in
boys. J Clin Endocrinol Metab 1989;69(3):563-70.
[40] Martha Jr. PM, Gorman KM, Blizzard RM, Rogol AD, Veldhuis
JD. Endogenous growth hormone secretion and clearance
rates in normal boys, as determined by deconvolution analy-
sis: relationship to age, pubertal status, and body mass. J Clin
Endocrinol Metab 1992;74(2):336-44.
[41] Christoforidis A, Maniadaki I, Stanhope R. Growth hormone/
insulin-like growth factor-1 axis during puberty. Pediatr
Endocrinol Rev 2005;3(1):5-10.
[42] Jaffe CA, Ocampo-Lim B, Guo W, Krueger K, Sugahara I,
DeMott-Friberg R, et al. Regulatory mechanisms of growth hor-
mone secretion are sexually dimorphic. J Clin Invest 1998;102(1):
153-64.
[43] Riggs BL, Khosla S, Melton III LJ. Sex steroids and the con-
struction and conservation of the adult skeleton. Endocr Rev
2002;23(3):279-302.
[44] Mauras N. Growth hormone and sex steroids. Interactions in
puberty. Endocrinol Metab Clin North Am 2001;30(3):529-44.
[45] Kronenberg HM. Developmental regulation of the growth
plate. Nature 2003;423(6937):332-6.
[46] Green H, Morikawa M, Nixon T. A dual effector theory of
growth-hormone action. Differentiation 1985;29(3):195-8.
[47] Sjogren K, Liu JL, Blad K, Skrtic S, Vidal O, Wallenius V,
et al. Liver-derived insulin-like growth factor I (IGF-I) is
the principal source of IGF-I in blood but is not required

for postnatal body growth in mice. Proc Nat Acad Sci USA
1999;96(12):7088-92.
[48] Yakar S, Liu JL, Stannard B, Butler A, Accili D, Sauer B, et al.
Normal growth and development in the absence of hepatic insu-
lin-like growth factor I. Proc Nat Acad Sci USA 1999;96(13):7324-9.
[49] Stratikopoulos E, Szabolcs M, Dragatsis I, Klinakis A,
Efstratiadis A. The hormonal action of IGF1 in postnatal mouse
growth. Proc Nat Acad Sci USA 2008;105(49):19378-19383.
[50] Lupu F, Terwilliger JD, Lee K, Segre GV, Efstratiadis A. Roles
of growth hormone and insulin-like growth factor 1 in mouse
postnatal growth. Dev Biol 2001;229(1):141-62.
[51] Merriman HL, La Tour D, Linkhart TA, Mohan S, Baylink DJ,
Strong DD. Insulin-like growth factor-I and insulin-like growth
factor-II induce c-fos in mouse osteoblastic cells. Calcif Tissue
Int 1990;46(4):258-62.
[52] Nilsson A, Swolin D, Enerback S, Ohlsson C. Expression of
functional growth hormone receptors in cultured human osteo-
blast-like cells. J Clin Endocrinol Metab 1995;80(12):3483-8.
[53] DiGirolamo DJ, Mukherjee A, Fulzele K, Gan Y, Cao X, Frank
SJ, et al. Mode of growth hormone action in osteoblasts. J Biol
Chem 2007;282(43):31666-31674.
[54] Birnbaum RS, Bowsher RR, Wiren KM. Changes in IGF-I
and -II expression and secretion during the proliferation
and differentiation of normal rat osteoblasts. J Endocrinol
1995;144(2):251-9.
[55] Canalis E, Rydziel S, Delany AM, Varghese S, Jeffrey JJ. Insulin-
like growth factors inhibit interstitial collagenase synthesis in
bone cell cultures. Endocrinology 1995;136(4):1348-54.
[56] Rydziel S, Delany AM, Canalis E. Insulin-like growth factor I
inhibits the transcription of collagenase 3 in osteoblast cultures.
J Cell Biochem 1997;67(2):176-83.
[57] Zhao G, Monier-Faugere MC, Langub MC, Geng Z, Nakayama
T, Pike JW, et al. Targeted overexpression of insulin-like growth
factor I to osteoblasts of transgenic mice: increased trabecu-
lar bone volume without increased osteoblast proliferation.
Endocrinology 2000;141(7):2674-82.
[58] Zhang M, Xuan S, Bouxsein ML, von Stechow D, Akeno N,
Faugere MC, et al. Osteoblast-speciic knockout of the insulin-
like growth factor (IGF) receptor gene reveals an essential role
of IGF signaling in bone matrix mineralization. J Biol Chem
2002;277(46):44005-44012.
[59] Spelsberg TC, Subramaniam M, Riggs BL, Khosla S. The
actions and interactions of sex steroids and growth factors/
cytokines on the skeleton. Mol Endocrinol 1999;13(6):819-28.
[60] Heath KE, Argente J, Barrios V, Pozo J, Diaz-Gonzalez F,
Martos-Moreno GA, et al. Primary acid-labile subunit dei-
ciency due to recessive IGFALS mutations results in postnatal
growth deicit associated with low circulating insulin growth
factor (IGF)-I, IGF binding protein-3 levels, and hyperinsu-
linemia. J Clin Endocrinol Metab 2008;93(5):1616-24.
[61] Efstratiadis A. Genetics of mouse growth. Int J Dev Biol
1998;42(7):955-76.
[62] Zhou Y, Xu BC, Maheshwari HG, He L, Reed M, Lozykowski
M, et al. A mammalian model for Laron syndrome produced
by targeted disruption of the mouse growth hormone recep-
tor/binding protein gene (the Laron mouse). Proc Nat Acad Sci
USA 1997;94(24):13215-13220.
[63] Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. Mice
carrying null mutations of the genes encoding insulin-like
growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell
1993;75(1):59-72.
[64] Baker J, Liu JP, Robertson EJ, Efstratiadis A. Role of insulin-
like growth factors in embryonic and postnatal growth. Cell
1993;75(1):73-82.
[65] Beamer WH, Eicher EM. Stimulation of growth in the little
mouse. J Endocrinol 1976;71(1):37-45.